Group items tagged

Study conducted and completed to evaluate the efficacy, acceptability, and safety of Axid Oral Solution versus placebo in the treatment of gastroesophageal reflux disease (GERD) in infants age 30 days up to 1 year.

Completed study assessed the pharmacokinetics and safety of dexlansoprazole, once daily (QD), in pediatric subjects with symptomatic Gastroesophageal Reflux Disease.

The mission of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition is to advance understanding of normal development, physiology and pathophysiology of diseases of the gastrointestinal tract and liver in children, improve quality of care by fostering the dissemination of this knowledge through scientific meetings, professional and public education, and policy development, and serve as an effective voice for members and the profession.". The membership of NASPGHAN consists of more than 1400 pediatric gastroenterologists, predominantly in 46 states, the District of Columbia, Puerto Rico, Mexico and 8 provinces in Canada.\n

The Children's Digestive Health and Nutrition Foundation (CDHNF) has a single goal: to improve the treatment and management of gastrointestinal, hepatobiliary, pancreatic and nutritional disorders in children. Through our work, we provide information and resources to parents, patients, and medical professionals dealing with these disorders. CDHNF was founded by the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN), a professional society of more than 1400 pediatric gastroenterologists, to promote awareness and research of pediatric digestive and nutritional disorders, including:\n

Completed study sponsored by University Hospital, Ghent assessing Pharmacokinetics of Enteral Omeprazole Suspension in Patients With Cerebral Palsy and Mental Retardation. Trial aims to compare the pharmacokinetics of omeprazole administered through the gastrostomy tube as a suspension in pediatric patients with cerebral palsy and mental retardation versus the pharmacokinetics of omeprazole administered as a multi-unit-pellet system (MUPS®).